WuXi Biologics (HKG:2269), a China-based global Contract Research, Development, and Manufacturing Organisation (CRDMO), announced on Monday that it has entered into a licence and research service agreement with US biopharmaceutical company Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) for an innovative trispecific T-cell Engager (TCE) for the treatment of B-cell mediated autoimmune diseases.
Through this agreement Vertex gains exclusive global rights to develop and commercialise an innovative trispecific TCE at the preclinical stage designed for the treatment of B-cell mediated autoimmune diseases.
WuXi Biologics will receive an upfront payment and is eligible to receive development, regulatory, and sales milestone payments, as well as royalty payments. In addition, WuXi Biologics will provide Vertex with contract research and development services on novel next-generation TCEs.
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA